Member Info for Early_Bird

call your broker mate. I think some arent trading it today yet, if you call them and give them a shove they may speed things up

ready to push up! be great to finish on 4p+ today

its opening today by the looks of it! AIM dont see the reason to suspend until EGM

Very nice. Well there we have it, back in action 19th April, 8 to 1 consolidatiom with price of raise will be 3p equivalent (24p). Good thing is dont think any existing holders will be interested in selling at that price should do very nicely from the word go. Need to digest the RNS but all sounds very good.

Agree on that Wizzkid, I m a holder here and am waiting patiently for the next update however I do think most are setting their expectations a little high. Personally be happy with 6p re list price any less I would be dissapointed given the big chat from the people involved when this first listed. All speculation until we hear more.

I should think we will hear more soon seeing as the book building process has been underway the past few weeks for this money they want to raise. As I understand it this will be more like an IPO with us being the pre IPO holders rather than traditional RTO so process should be much faster.

Hi mate, very good thanks, hope you are too! Im still like a little kid waiting for Xmas here lol

Anyone want confirmation on how massive having a succesful phase 3 drug result is then check out GWP's announcement today http://www.lse.co.uk/share-regulatory-news.asp?shareprice=GWP&ArticleCode=l4x7sdbk&ArticleHeadline=Epidiolex_Positive_Phase_3_Pivotal_Study_Results Look at the market cap... FAST not only have phase 3 drug but its EU approved for marketting.

Director MG loading up at a 50% premium to IPO Very reassuring and beginning to think something very exciting is coming this way in the not too distant.

I would say once we have a drug on the market with revenue stream in coming we will be looking to build our PF of orphan drugs and develop those in the earlier phases that we will already have. Very interesting with the likes of french pharma giant Sonfi & also Shire who are on a shopping spree currently buying out Orphan drug start ups and both competing to dominate the space. Contacts we have here are second to none for getting exposure to the major players as our chairman founded one of them!

Book building process is currently underway so I think we will get the admission document once they finalise the strike price. I'm hopeful we will hear something this month. Like I say, looks like this has been incredibly well organised behind the scences in the lead up to suspension. The ducks were being lined up long before even the vote change to biopharma.

Yes rule of thumb for RTO is 6 months however with fast I think we could well be back in action as soon at April. Roadshow and bookbuilding process is already underway, once this finishes I assme we will get all the details of the transaction to vote on.

Agree but the quality of management team put together here simply does not belong on AIM, its destined for things much greater. Biopharma companies have huge premiums attached to them esp on nasdaq and this is clearly where we will be headed. Get those shares in the ISA and enjoy the story unfolding.

Will add, the good thing here is I dont think we will have long to find out all the details. Most companies in RTO spend 6months in suspension. The forward planning, organisation of CF here has exceeded my wildest expectations to be honest. He has shoved two fingers up to doubters (not naming anyone in particular) and done it with actions not words. As I have always said, this deal has been in the making for years and not months. We have the founder of Shire as chairman, CEO and CFO have both directed nasdaq listed companies... we have a certified Orphan drug which is EU approved for marketing and will have a heft chunk of cash to get this in to shelves an also develop other drugs. Doesnt take a rocket scientist to work out this is/will be one of the biggest success stories on AIM this year.

Radar im still in fits of laughter about how badly you timed your deramping close of play friday of last weekend, followed by huge news in the sunday papers and suspension first thing monday. Good work Son. Think a good few were having a chuckle about that. Nothing wrong with having lofty ambitions, for me id actually half prefer it priced to rocket on its return say 4p with huge initial upside rather than coming straight back at 10p. Reason being it would provide a better platform for a big steady rise rather than existing holders all scrambling to sell out on relist for immediate 3 bag returns. At 4p I cant see many if any existing holders selling and huge demand would press it up on the open market could do 100% and everyone is a winner. Again all depends on how much equity is given to Amryt and at what price to find out our new MC, listing price and cash. Very excited.

On re listing we will have an approved drug by the European regulator, which will be developed as a treatment for epidermolysis bullosa (EB), a genetic skin disease that causes painful blisters to form as a result of the slightest friction. Going public will enable the company to scale more quickly. The disease was the subject of a well-known Channel 4 documentary entitled The Boy Whose Skin Fell Off. Truly awful condition and its nice to be involved in a company that will hopefully help unfortunate people with this disease. On further research "There's currently no cure for epidermolysis bullosa (EB), but treatment can help ease and control symptoms." Interestingly one of the emerging treatments for this disease, a modest sized private company Scioderm Inc, has just had a huge buyout in August 2015 by Amicus with a deal valued at $950M for just this one drug, Zorblisa (looks to be administered as a cream) and its currently in phase III trials.. essentially its a cream that helps heal wounds faster... So to me it looks like in our RTO we have a rival drug coming to the market... Episalvan (previously Oleogel-S10) has obtained the Orphan Drug Designation (which I hadn't realised in my previous post!) for the treatment of hereditary skin disorder Epidermolysis bullosa (EB) from the European Commission. This has passed phase III trials and more recently has just received full EU approval for marketing so to me looks to be in a very similar phase to Zorblisa. Its administered as a gel and also helps wounds heal faster... $950M is a chunky number.... seems to be big value in treatment for this disease. Maybe Harry and co. have plans to fast track Episalvan to the shelf before Zorblisa? No better man for the job.

The two companies that Fast (Amryt) are buying will be issued shares in lieu of cash so this will be on top of the £20M fundraise. The quantity of these and price they will be issued at is unknown so the resulting market capital and listing price will be an uknown quantity until we hear more from the company. Essentially we will have £30M cash, a series of drugs in different phases with one EU approved (Episalvan) which is ready to go in to the marketting phase which is huge. Episalvan has the proven ability to reduce the healing time of wounds where the upper layers of the skin have been damaged, for example by a burn or during surgical skin grafting - so scope with second degree burns etc to market as a gel to help healing. Im assuming the next step for this particular drug is to get Orphan drug status granted on it for treatment of the rare disease epidermolysis bullosa (EB) which will bring with it a whole new array of financial incentives (again Harry Stratford has got extensive capabilites in this field through Shire which specialised on Orphan drugs). There are also a number of other drugs in phase 2/3 which will be coming to market at a later stage. The £30M cash will be used to market the newly approved drug plus also develop the other drugs. The beauty we have here is a drug with full EU approval ready to go market phase (huge).. a peer comparisson of biopharma in this similar stage are in the £100s of millions. Obviously they will want to price the deal to be attractive so it is set to rocked upon re listing. Essentially this is like an IPO where us holders are in at the "pre IPO" discount price. A number of road shows this week with retail and institutions so will be very interesting to see what interest this deal has in the city... I guess this, along with the equity dilution for acquiting the two companies, will dictate the fundraise/listing price. As people have mentioned I would assume it will be above 3.8p to save restructuring. CF bought his shares at 4p so that may be a good starting point as the floor IMHO. GLA

The deal will be being valued as we speak. As Dan says we can be very comfortable this is coming back at multiples of cash given the advanced stage EU approved drug and calibre of management. Very roughly a £20m raise at 10p would equate to a MC of £50M with £30M in cash.... Look at the other 4 listed peers with a drug in such an advanced stage and the valuations are big. Very big. $billion range. Keeping feet on the ground here but one thing is 100% certain is we have the best seats in the house to watch this all unfold!! Could be one of the biggest stories on AIM this year IMHO. GLA

As I was posting a month or two back... these orphan drugs are very big business although niche. Uncanny that the founder of Shire, a multi billion £ pharma company that specialises in Orphan drugs will now be chairing this new company...that by the way is currently valued just at cash! seriously excited. Article from FT that I posted a month or two back well worth a read: http://www.ft.com/cms/s/0/594cf986-271c-11e5-bd83-71cb60e8f08c.html "Orphan drugs might target small groups of patients, but they are increasingly big business. Pharmaceutical companies, from tiny biotech start-ups to Shire, the London-listed group with a market capitalisation of more than £30bn, are focusing on drugs for orphan diseases, lured by regulatory incentives and a low-volume, high-margin business model. Ever since the introduction of the US Orphan Drug Act 32 years ago, developing medicines for rare disease has become the so-called “Goldilocks option” for some pharma companies. Groups selling orphan drugs are granted seven years of market exclusivity (against five years for most medicines), along with generous tax credits. Because they target diseases that do not already have treatments, they also tend to benefit from other regulatory initiatives designed to get drugs to market more quickly. Once approved, the drugs often have a ready-made audience: many patients with rare diseases are well organised in advocacy groups, have been waiting for years for a treatment, and are primed to request the medicine from their doctors once it is available. Global sales of orphan drugs are expected to jump as more companies enter this field, rising by 11 per cent each year to reach $176bn in 2020, according to EvaluatePharma, the research group. Investors have taken notice. In the past year, the value of US biotech companies focused on rare diseases has risen by about 56 per cent, according to the Orphan Disease Index, assembled by JMP Securities, a San Francisco investment bank. That performance was even better than the broader Nasdaq biotech index, which is up by roughly 37 per cent over the same period, and smashed the S&P 500 index, which is 5 per cent higher." Have a good day folks.

The so-called reverse takeover will allow Amryt to gain access to public markets without the expensive and often tortuous IPO process. The process, which will require approval by Fastnet shareholders, involves Fastnet issuing enough new shares to Amryt to enable the latter company to take control. Amryt is to embark on a fundraising process via issuing new shares, which will fund the new entity's product development programme. The cash will transfer to the company when the reverse takeover is complete. Davy Stockbrokers will lead the fundraising and an investor roadshow is believed to be commencing as early as next week. The new entity will be chaired by Harry Stratford, the founder of pharmaceuticals giant Shire. Joseph Wiley, formerly medical director of Astellas Pharma, will be chief executive and Trinity Biotech's chief financial officer, Rory Nealon, will hold the same role at Amryt. Amryt has signed conditional deals to buy two companies - Som Pharmaceuticals and Birken - which will complete if the reverse takeover goes ahead. Amryt would then have a product, approved by the European regulator, which will be developed as a treatment for epidermolysis bullosa (EB), a genetic skin disease that causes painful blisters to form as a result of the slightest friction. Going public will enable the company to scale more quickly. The disease was the subject of a well-known Channel 4 documentary entitled The Boy Whose Skin Fell Off. Other products for treating other rare diseases are in the pipeline. It's believed that Dublin-based Raglan Capital had helped to put Amryt together. The deal is in line with Fastnet's new investing policy that was approved by shareholders at a general meeting in August. Read more: http://www.independent.ie/business/irish/fastnet-swoops-for-drug-maker-in-new-reverse-takeover-bid-34470543.html